Medical device maker Medtronic is switching to $16 billion in financing to complete its purchase of Ireland-based competitor Covidien a few weeks after federal regulators issued rules designed to curb overseas acquisitions that cut tax U.S. tax bills.
The Minneapolis company says it will use financing instead of cash from its foreign subsidiaries to help close the nearly $43 billion deal it announced in June. A company spokesman says the change was in response to the new rules from the U.S. Treasury Department.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.